News
TERN
52.69
-0.04%
-0.02
Terns Pharmaceuticals Is Maintained at Overweight by JP Morgan
Dow Jones · 2d ago
Terns Pharmaceuticals Price Target Raised to $44.50/Share From $44.00 by JP Morgan
Dow Jones · 2d ago
JP Morgan Maintains Overweight on Terns Pharmaceuticals, Raises Price Target to $44.5
Benzinga · 2d ago
Weekly Report: what happened at TERN last week (0406-0410)?
Weekly Report · 3d ago
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN
Barchart · 6d ago
Merck & Co.'s Quarterly Earnings Preview: What You Need to Know
Barchart · 04/09 08:31
Why Terns Pharmaceuticals Stock Rocked the Market in March
The Motley Fool · 04/08 18:20
Terns Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
TipRanks · 04/08 14:09
TERNS PHARMACEUTICALS INC <TERN.O>: LEERINK PARTNERS CUTS TO MARKET PERFORM FROM OUTPERFORM; CUTS TARGET PRICE TO $53 FROM $58
Reuters · 04/08 13:33
TERNS PHARMACEUTICALS INC <TERN.O>: WILLIAM BLAIR CUTS TO MARKET PERFORM RATING
Reuters · 04/08 10:50
U.S. RESEARCH ROUNDUP-3M, CME Group, TransDigm Group
Reuters · 04/08 08:13
Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
Benzinga · 04/07 18:28
What's Going On With Merck Stock Tuesday?
Benzinga · 04/07 16:46
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV) and Terns Pharmaceuticals (TERN)
TipRanks · 04/07 16:40
Terns Pharmaceuticals downgraded to Market Perform from Outperform at William Blair
TipRanks · 04/07 16:40
Unusually active option classes on open April 7th
TipRanks · 04/07 15:03
Merck begins tender offer to buy Terns Pharmaceuticals
Seeking Alpha · 04/07 13:10
Merck begins tender offer for Terns at USD 53 a share
Reuters · 04/07 13:01
MERCK BEGINS TENDER OFFER TO ACQUIRE TERNS PHARMACEUTICALS, INC.
Reuters · 04/07 13:00
Weekly Report: what happened at TERN last week (0330-0403)?
Weekly Report · 04/06 09:44
More
Webull provides a variety of real-time TERN stock news. You can receive the latest news about Terns Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.